Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1947 5
1948 22
1949 40
1950 12
1951 8
1952 21
1953 32
1954 25
1955 21
1956 41
1957 23
1958 72
1959 39
1960 30
1961 56
1962 62
1963 148
1964 216
1965 125
1966 120
1967 189
1968 194
1969 224
1970 198
1971 219
1972 136
1973 174
1974 178
1975 123
1976 121
1977 91
1978 86
1979 90
1980 100
1981 76
1982 84
1983 68
1984 91
1985 100
1986 98
1987 105
1988 109
1989 112
1990 103
1991 106
1992 108
1993 80
1994 94
1995 95
1996 81
1997 92
1998 77
1999 82
2000 107
2001 86
2002 107
2003 90
2004 106
2005 127
2006 167
2007 179
2008 195
2009 219
2010 230
2011 274
2012 257
2013 324
2014 368
2015 420
2016 523
2017 595
2018 642
2019 651
2020 649
2021 581
2022 675
2023 561
2024 208

Text availability

Article attribute

Article type

Publication date

Search Results

12,334 results

Results by year

Filters applied: . Clear all
Page 1
Mechanisms of Polymyxin Resistance.
Moffatt JH, Harper M, Boyce JD. Moffatt JH, et al. Adv Exp Med Biol. 2019;1145:55-71. doi: 10.1007/978-3-030-16373-0_5. Adv Exp Med Biol. 2019. PMID: 31364071 Review.
Furthermore, some Gram-negative species, such as Neisseria meningitidis, Proteus mirabilis and Burkholderia spp., are intrinsically resistant to the action of polymyxins. Most identified polymyxin resistance mechanisms in Gram-negative bacteria involve changes to the lipop …
Furthermore, some Gram-negative species, such as Neisseria meningitidis, Proteus mirabilis and Burkholderia spp., are intrinsically resistan …
Polymyxin combination therapy for multidrug-resistant, extensively-drug resistant, and difficult-to-treat drug-resistant gram-negative infections: is it superior to polymyxin monotherapy?
Ardebili A, Izanloo A, Rastegar M. Ardebili A, et al. Expert Rev Anti Infect Ther. 2023 Apr;21(4):387-429. doi: 10.1080/14787210.2023.2184346. Epub 2023 Mar 8. Expert Rev Anti Infect Ther. 2023. PMID: 36820511 Review.
AREAS COVERED: The rapid growing of multi-resistant GNB as well as the considerable deceleration in development of new anti-infective agents have made polymyxins (e.g. polymyxin B and colistin) a mainstay in clinical practices as either monotherapy or combination therapy. …
AREAS COVERED: The rapid growing of multi-resistant GNB as well as the considerable deceleration in development of new anti-infective agents …
Rescuing the Last-Line Polymyxins: Achievements and Challenges.
Nang SC, Azad MAK, Velkov T, Zhou QT, Li J. Nang SC, et al. Pharmacol Rev. 2021 Apr;73(2):679-728. doi: 10.1124/pharmrev.120.000020. Pharmacol Rev. 2021. PMID: 33627412 Free PMC article. Review.
Therefore, knowledge on polymyxins had been scarce until recently, when enormous efforts have been made by several research teams around the world to elucidate the chemical, microbiological, pharmacokinetic/pharmacodynamic, and toxicological properties of polymyxins …
Therefore, knowledge on polymyxins had been scarce until recently, when enormous efforts have been made by several research teams aro …
Overview of polymyxin resistance in Enterobacteriaceae.
Silva KED, Rossato L, Leite AF, Simionatto S. Silva KED, et al. Rev Soc Bras Med Trop. 2022 Feb 25;55:e0349. doi: 10.1590/0037-8682-0349-2021. eCollection 2022. Rev Soc Bras Med Trop. 2022. PMID: 35239902 Free PMC article. Review.
This review highlights the current information regarding the mechanisms of resistance to polymyxins and their molecular epidemiology. Knowledge of the resistance mechanisms and epidemiology of these pathogens is critical for the development of novel antibacterial agents an …
This review highlights the current information regarding the mechanisms of resistance to polymyxins and their molecular epidemiology. …
Discovery of Novel Polymyxin-Like Antibiotics.
Velkov T, Roberts KD. Velkov T, et al. Adv Exp Med Biol. 2019;1145:343-362. doi: 10.1007/978-3-030-16373-0_20. Adv Exp Med Biol. 2019. PMID: 31364086 Review.
However, their effective use as antibiotic drugs in the clinical setting is still plagued by significant toxicity issues, in particular their potential for nephrotoxicity. Furthermore, resistance to the polymyxins has begun to emerge in the clinic, which implies a total la …
However, their effective use as antibiotic drugs in the clinical setting is still plagued by significant toxicity issues, in particular thei …
Conclusion.
Nation RL. Nation RL. Adv Exp Med Biol. 2019;1145:363-364. doi: 10.1007/978-3-030-16373-0_21. Adv Exp Med Biol. 2019. PMID: 31364087 Review.
This chapter briefly reviews the progress that has been made in understanding the key chemical, microbiological and pharmacological properties of the polymyxins since they were resurrected for clinical use around the start of the current century. ...
This chapter briefly reviews the progress that has been made in understanding the key chemical, microbiological and pharmacological properti …
Polymyxin Susceptibility Testing and Breakpoint Setting.
Turnidge J, Sei K, Mouton J. Turnidge J, et al. Adv Exp Med Biol. 2019;1145:117-132. doi: 10.1007/978-3-030-16373-0_9. Adv Exp Med Biol. 2019. PMID: 31364075 Review.
Susceptibility testing of polymyxins has been subject to intensive review and revision in recent years. ...
Susceptibility testing of polymyxins has been subject to intensive review and revision in recent years. ...
Polymyxin combinations: pharmacokinetics and pharmacodynamics for rationale use.
Bergen PJ, Bulman ZP, Saju S, Bulitta JB, Landersdorfer C, Forrest A, Li J, Nation RL, Tsuji BT. Bergen PJ, et al. Pharmacotherapy. 2015 Jan;35(1):34-42. doi: 10.1002/phar.1537. Pharmacotherapy. 2015. PMID: 25630411 Free PMC article. Review.
Considering the potential for rapid development of resistance to polymyxins, well-designed clinical trials that include higher-dose polymyxin regimens are urgently required to provide a more definitive answer regarding the role of polymyxin combination therapy compared wit …
Considering the potential for rapid development of resistance to polymyxins, well-designed clinical trials that include higher-dose p …
Inhibiting fatty acid synthesis overcomes colistin resistance.
Carfrae LA, Rachwalski K, French S, Gordzevich R, Seidel L, Tsai CN, Tu MM, MacNair CR, Ovchinnikova OG, Clarke BR, Whitfield C, Brown ED. Carfrae LA, et al. Nat Microbiol. 2023 Jun;8(6):1026-1038. doi: 10.1038/s41564-023-01369-z. Epub 2023 May 1. Nat Microbiol. 2023. PMID: 37127701
Treating multidrug-resistant infections has increasingly relied on last-resort antibiotics, including polymyxins, for example colistin. As polymyxins are given routinely, the prevalence of their resistance is on the rise and increases mortality rates of sepsis patie …
Treating multidrug-resistant infections has increasingly relied on last-resort antibiotics, including polymyxins, for example colisti …
Causes of polymyxin treatment failure and new derivatives to fill the gap.
Chiu S, Hancock AM, Schofner BW, Sniezek KJ, Soto-Echevarria N, Leon G, Sivaloganathan DM, Wan X, Brynildsen MP. Chiu S, et al. J Antibiot (Tokyo). 2022 Nov;75(11):593-609. doi: 10.1038/s41429-022-00561-3. Epub 2022 Sep 20. J Antibiot (Tokyo). 2022. PMID: 36123537 Review.
Polymyxins are a class of antibiotics that were discovered in 1947 from programs searching for compounds effective in the treatment of Gram-negative infections. ...These phenomena, along with bacterial tolerance to this antibiotic class, constitute important contributors t …
Polymyxins are a class of antibiotics that were discovered in 1947 from programs searching for compounds effective in the treatment o …
12,334 results
You have reached the last available page of results. Please see the User Guide for more information.